Team Ioannis Parodis
We perform clinical and translational research within the field of inflammation and autoimmunity, with a focus on systemic lupus erythematosus. Our research includes biomarker exploration, as well as investigation and prediction of effects of biological and non-biological immunomodulatory therapies on clinical, molecular, and patient-reported outcomes.
A separate research trajectory comprises projects within medical pedagogy.
Clinical and translational research within lupus and autoimmunity
Main focus: Precision medicine in autoimmune disease, with a particular focus on systemic lupus erythematosus (SLE) and its clinical manifestations.
Our goals: The overall goal of our research is to contribute to personalised management of people living with autoimmune disease, particularly SLE. Driven by the hypothesis that molecular patterns better inform treatment selection, we develop prediction models of treatment response and prognosis based on molecular patterns rather than clinical phenotypes.
Our research in brief: We study molecular phenotypes based on gene expression and protein levels in blood, urine, and tissues. We determine drug repurposing potentiality using systems biology and propose markers of disease activity, response to therapies, and prognosis, that are amenable to use in routine clinical practice. One of our objectives focuses on identification of peripheral markers in blood and urine that best mirror cellular and molecular profiling of kidney tissue from patients with lupus nephritis (LN).
Lupus in brief: SLE is a chronic, inflammatory, autoimmune disease that predominantly affects women of childbearing age. LN constitutes a severe, potentially life-threatening disease manifestation with still ill-defined pathogenesis, which affects 35–60% of patients with SLE.
Societal benefit: Our research is driven by simple but important aims. Findings from our projects are anticipated to have an unprecedented impact on the clinical care of patients with SLE and autoimmune diseases, contributing to improved quality of life and lower healthcare demand, including lower frequencies of hospitalisation. This in turn contributes to reduced healthcare costs, deceleration of organ damage accrual, and an overall decreased morbidity and mortality for patients with SLE.
Medical pedagogy: In a distinct research avenue, we examine the potential of virtual patients to enhance clinical reasoning skills within the realm of medical education using an innovative AI-embedded social robotic platform.
- EU - IHI/EFPIA
- Stiftelsen Konung Gustaf V:s 80-årsfond
- Svenska Läkaresällskapet
- Stiftelsen Professor Nanna Svartz
- Ulla och Roland Gustafssons donationsfond
- Region Stockholm
- Karolinska Institutet
- Bristol-Myers Squibb
Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus.
Lindblom J, Toro-Domínguez D, Carnero-Montoro E, Beretta L, Borghi MO, Castillo J, Enman Y, , Mohan C, Alarcón-Riquelme ME, Barturen G, Parodis I
J Autoimmun 2023 Apr;136():103025
Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials.
Gomez A, Jägerback S, Sjöwall C, Parodis I
Rheumatology (Oxford) 2023 May;():
Molecular architecture of proliferative lupus nephritis as elucidated using 50-plex imaging mass cytometry proteomics.
Louis Sam Titus ASC, Tan Y, Tran P, Lindblom J, Ivbievbiokun M, Xu Y, Zheng J, Parodis I, Cai Q, Chang A, Chen SH, Zhao M, Mohan C
Clin Immunol 2023 Sep;254():109713
B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab.
Parodis I, Gomez A, Lindblom J, Chow JW, Sjöwall C, Sciascia S, Gatto M
Int J Mol Sci 2022 Nov;23(22):
Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab.
Parodis I, Gomez A, Chow JW, Borg A, Lindblom J, Gatto M
Front Immunol 2022 ;13():796508
Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab.
Palazzo L, Lindblom J, Çetrez N, Ala H, Parodis I
Rheumatology (Oxford) 2023 May;():
Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis.
Parodis I, Adamichou C, Aydin S, Gomez A, Demoulin N, Weinmann-Menke J, Houssiau FA, Tamirou F
Rheumatology (Oxford) 2020 Nov;59(11):3424-3434
EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis.
Parodis I, Girard-Guyonvarc'h C, Arnaud L, Distler O, Domján A, Van den Ende CHM, Fligelstone K, Kocher A, Larosa M, Lau M, Mitropoulos A, Ndosi M, Poole JL, Redmond A, Ritschl V, Alexanderson H, Sjöberg Y, von Perner G, Uhlig T, Varju C, Vriezekolk JE, Welin E, Westhovens R, Stamm TA, Boström C
Ann Rheum Dis 2023 Jul;():
Clinical Reasoning Needs to Be Explicitly Addressed in Health Professions Curricula: Recommendations from a European Consortium.
Parodis I, Andersson L, Durning SJ, Hege I, Knez J, Kononowicz AA, Lidskog M, Petreski T, Szopa M, Edelbring S
Int J Environ Res Public Health 2021 Oct;18(21):